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Abstract
Aims Recessive PDX1 (IPF1) mutations are a rare cause of pancreatic agenesis, with three cases reported worldwide. A
recent report described two cousins with a homozygous hypomorphic PDX1 mutation causing permanent neonatal
diabetes with subclinical exocrine insufficiency. The aim of our study was to investigate the possibility of hypomorphic
PDX1 mutations in a large cohort of patients with permanent neonatal diabetes and no reported pancreatic hypoplasia
or exocrine insufficiency.
Methods PDX1 was sequenced in 103 probands with isolated permanent neonatal diabetes in whom ABCC8, KCNJ11
and INS mutations had been excluded.
Results Sequencing analysis identified biallelic PDX1 mutations in three of the 103 probands with permanent neonatal
diabetes (2.9%). One proband and his affected brother were compound heterozygotes for a frameshift and a novel
missense mutation (p.A34fsX191; c.98dupC and p.P87L; c.260C>T). The other two probands were homozygous for
novel PDX1 missense mutations (p.A152G; c.455C>G and p.R176Q; c.527G>A). Both mutations affect highly
conserved residues located within the homeobox domain. None of the four cases showed any evidence of exocrine
pancreatic insufficiency, either clinically, or, where data were available, biochemically. In addition a heterozygous
nonsense mutation (p.C18X; c.54C>A) was identified in a fourth case.
Conclusions This study demonstrates that recessive PDX1 mutations are a rare but important cause of isolated
permanent neonatal diabetes in patients without pancreatic hypoplasia/agenesis. Inclusion of the PDX1 gene in mutation
screening for permanent neonatal diabetes is recommended as a genetic diagnosis reveals the mode of inheritance, allows
accurate estimation of recurrence risks and confirms the requirement for insulin treatment.
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Introduction
Permanent neonatal diabetes diagnosed before 6 months is a
rare condition with a reported incidence of approximately
1:200 000 births in Caucasian populations [1]. A genetic
diagnosis is possible for ~70% of cases [2], with the majority
of patients harbouring mutation(s) in the potassium channel
genes (KCNJ11 or ABCC8) or in the INS gene [2].
Permanent neonatal diabetes attributable to pancreatic
agenesis is very rare and, until recently, the causal gene was
identified just in five cases, two of them caused by mutations
in the PTF1A gene [3] and three with biallelic PDX1
mutations [4–6]. Recently, heterozygous mutations in the
transcription factorGATA6were found to be the major cause
of pancreatic agenesis in humans, with 15 cases reported [7].
PDX1 is a member of the homeodomain family of proteins
necessary for pancreatic development. Mice with a homozy-
gous null mutation of Pdx1 lack a pancreas. Pdx1+/– mice do
not show any relevant phenotype at birth, but haploinsuf-
ficiency of Pdx1 in b-cells causes impaired glucose tolerance
in older mice (18 months) [8].
Biallelic mutations in PDX1 are a known cause of
pancreatic agenesis. The first homozygous PDX1 mutation
was reported in an infant with pancreatic agenesis [5], with a
homozygous deletion of a single nucleotide, resulting in a
premature termination codon (Pro63fsX60). The sameCorrespondence to: Sian Ellard. E-mail: sian.ellard@nhs.net
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mutation was later reported in a second case of pancreatic
agenesis [6]. A third case [4] was a compound heterozygote
for two PDX1 missense mutations (E164D, E178K) that
were shown to decrease the protein half-life. Recently,
Nicolino et al. [9] reported a family where two cousins with
permanent neonatal diabetes and no clinical sign of pancre-
atic insufficiency harboured a homozygous missense muta-
tion in PDX1 (E178G). Biochemical studies revealed
subclinical evidence of exocrine insufficiency in both infants.
Functional studies showed that the E178G mutant protein
had reduced transactivation activity, but normal localization,
expression level and chromatin occupancy. They hypothe-
sized that E178G is a hypomorphic mutation, causing the
expression of a protein that still retains some residual
activity, leading to a milder phenotype.
The finding that PDX1 mutations can cause permanent
neonatal diabetes in the absence of clinical features of
exocrine pancreatic insufficiency prompted us to screen a
cohort of 103 patients with isolated permanent neonatal
diabetes to determine the contribution of biallelic hypomor-
phic PDX1 mutations to the aetiology of this disease.
Materials and methods
Patient cohort
Mutation testing of PDX1 was performed in 103 probands
with isolated permanent neonatal diabetes diagnosed before
6 months (median age at diagnosis 13 weeks; interquartile
range 1.5–24). The median birthweight was 2600 g (inter-
quartile range 1800–3250). Seventeen out of 103 were born
to consanguineous parents. Mutations in ABCC8, KCNJ11
and INS had been excluded. We also excluded EIF2AK3
mutations in patients born to consanguineous parents. None
of the patients was reported to have pancreatic agenesis/
hypoplasia or show clinical signs of exocrine insufficiency
(defined as need for enzyme supplementation therapy). The
relevant clinical information was provided by the referring
clinicians. The study was conducted in accordance with the
Declaration of Helsinki with informed parental consent
given on behalf of children.
Molecular genetic analysis
We screened the coding sequence and intron–exon boundaries
of thePDX1 gene (NM_000209.3) using Sanger sequencing at
standard conditions and following manufacturers’ protocols
(primers available on request). For case IV we also sequenced
the promoter region (3189 bp), the intron and the 3’ untrans-
lated region. Sequencing reactions were run on an ABI3730
capillary machine (Applied Biosystems, Warrington, UK) and
analysed using Mutation Surveyor, v3.98 (SoftGenetics, State
College, PA, USA). We used the bioinformatic tools SIFT and
PolyPhen to predict the effect of novel variants on the PDX1
protein (protein reference NP 000200.1).
Results
Molecular genetic testing
Biallelic mutations in PDX1 were found in three of the 103
probands with isolated permanent neonatal diabetes (2.9%)
and a heterozygous nonsense mutation was identified in a
fourth case.
A male infant (I-1, Table 1) and his affected brother (I-2,
Table 1) were compound heterozygotes for a frameshift and a
Table 1 Clinical and molecular characteristics of five cases with neonatal diabetes and PDX1 mutations
No. Mutation Protein Birthweight
Age at
diagnosis
(days)
Pancreatic
imaging
result
Pancreatic
imaging
modality
Pancreatic
exocrine:
clinical
Pancreatic
exocrine:
biochemistry
Current
insulin
daily dose
I-1 c. 98dup/
259C>T
A34CfsX191/
P87L
2.5 kg/
40 weeks
18 Normal
pancreatic
size
Ultrasound
sonography
Asymptomatic Faecal elastase
286 lg/g stool
(Reference
> 200 lg/g)
0.52 U/kg
I-2 c. 98dup/
259C>T
A34CfsX191/
P87L
2.76 kg/
40 weeks
18 Normal
pancreatic
size
Ultrasound
sonography
Asymptomatic Faecal elastase
211 lg/g stool
(Reference
> 200 lg/g)
0.39 U/kg
II c. 455C>G/
455C>G
A152G/
A152G
1.75 kg/
40 weeks
2 Normal
pancreatic
size
Computed
tomography
abdomen
Asymptomatic Not known 0.6 U/kg
III c. 527G>A/
527G>A
R176Q/
R176Q
1.70 kg,
gestational age
not recorded
20 Normal
pancreatic
size
Ultrasound
sonography
Asymptomatic Not known 0.7 U/kg
IV c. 54C>A/
Normal
C18X/
Normal
1.60 kg/
37 weeks
8 Head of
pancreas
identified
Ultrasound
sonography
Asymptomatic Faecal
chymotrypsin
0.36 mkat/kg
(Reference
> 0.32 mkat/l)
0.53 U/kg
e198
ª 2013 The Authors.
Diabetic Medicine ª 2013 Diabetes UK
DIABETICMedicine PDX1 and neonatal diabetes  E. De Franco et al.
novel missense mutation (p.A34CfsX191; c.98dupC and
p.P87L; c.260C>T). The P87L mutation affects a residue
located within the proline-rich region of the PDX1 protein
(Fig. 1) and was inherited from the mother (see also Support-
ing Information, Fig. S1). Both the mother and her sister are
homozygous for P87L (their parents are first cousins) and had
gestational diabetes. The father, diagnosed with diabetes at
32 years of age, is heterozygous for the frameshift mutation
and inherited the mutation from his unaffected mother.
A second proband (II, Table 1) harbours a homozygous
mutation in exon 2 of PDX1 (p.A152G; c.455C>G) and
both unaffected parents are heterozygous. Another novel
homozygous missense mutation (R176Q; c.527G>A) was
found in a female infant (III, Table 1). Her unaffected father
is heterozygous for the same missense mutation; DNA from
the unaffected mother was not available for testing. Both the
A152G and R176Q mutations affect highly conserved
residues located in the homeodomain of PDX1 (Fig. 1) and
were predicted to be deleterious by SIFT and PolyPhen-2.
Heterozygous PDX1 base substitutions were found in four
probands. One was a novel nonsense mutation (p.C18X;
c.54C>A) (case IV, Table 1). Sequencing of the intron and
regulatory regions (promoter and 3’ untranslated region) of
PDX1 failed to identify a second mutation. Analysis of
parental samples showed that the mutation was inherited
from the unaffected father.
Two patients were heterozygous for synonymous variants
(p.F100F; c.300C>T and p.P244P; c.732C>G) that are
unlikely to be pathogenic. We also found a novel missense
variant, p.P93R; c.278C>G that affects a residue within a
highly variable region of the gene and is likely to be a rare
polymorphism.
Clinical characteristics of patients with PDX1 mutations
The first family includes two siblings with permanent
neonatal diabetes. Both the proband (I-1, Table 1) and his
affected brother were diagnosed with diabetes at 18 days
(blood glucose 20.9 mmol/l and 20.6 mmol/l, respectively).
Both siblings are treated with insulin pumps. Ultrasound
sonography showed a normal pancreas. There were no
clinical features of exocrine pancreatic insufficiency and
faecal elastase was within the normal range (Table 1).
Proband II and III were born to consanguineous parents
(first cousins). Proband II was born at 40 weeks’ gestation
and developed diabetes at 2 days of life (44.4 mmol/l). The
third patient (III, Table 1) was diagnosed with neonatal
diabetes mellitus at 20 days (27 mmol/l). There was no
clinical evidence of exocrine pancreatic insufficiency in either
of these cases, but biochemical testing had not been
performed as it was not indicated on clinical grounds.
Finally, we report a female infant in whom a single
inactivating PDX1 mutation was identified. The patient (IV,
Table 1) was born to unrelated parents without diabetes. She
was diagnosed with diabetes at 20 days and insulin treat-
ment commenced. Ultrasound sonography was performed
when she was 2 weeks old and showed that at least the head
of the pancreas was present. Her faecal chymotrypsin level
was normal.
Discussion
Biallelic mutations in PDX1 were identified in four patients
from three families with isolated permanent neonatal diabe-
tes. None were reported to have pancreatic agenesis or
exocrine pancreatic insufficiency and, in the two cases where
faecal elastase was measured, levels were normal.
The first patient and his affected brother are compound
heterozygotes for a missense (P87L) and a frameshift
mutation (A34CfsX191). Their mother was born to consan-
guineous parents and is homozygous for the P87L mutation.
This mutation is likely to be hypomorphic as she did not
develop diabetes until adulthood when she was diagnosed
with gestational diabetes during her first pregnancy. The
father is heterozygous for the frameshift mutation and any
future offspring will be at 50% risk of permanent neonatal
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FIGURE 1 (a) Schematic representation of the PDX1 protein and location of the mutations identified in the four reported cases. The transactivation
domain is highlighted in red. The region highlighted in blue is the homeobox domain of the PDX1 protein. (b) Amino acid conservation in the
homeodomain. The red rectangles highlight the location of the two homeodomain mutations found in our cohort (cases II and III). The black dashed
line indicates the position of the hypomorphic mutation reported by Nicolino et al. [9].
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diabetes. The two other probands, both from consanguine-
ous families, harbour homozygous missense mutations
affecting highly conserved residues within the homeobox
domain of the protein (respectively p.R176Q and p.A152G).
The R176Q mutation affects a residue just two amino acids
upstream of the mutation (E178G) reported by Nicolino
et al. [9] (Fig. 1).
A fourth patient was found to be heterozygous for a novel
PDX1 nonsense mutation (C18X). The mutation is predicted
to introduce a stop codon in the first exon of PDX1 and it is
likely that the mutated transcript is subject to nonsense
mediated decay. She inherited this mutation from her
unaffected father but sequencing analysis of the intronic
and regulatory regions of PDX1 failed to identify a second,
maternal mutation. This C18X mutation is predicted to
cause neonatal diabetes in the homozygous, but not hetero-
zygous state. Our results cannot distinguish between the
alternative possibilities of an undetected maternal mutation
(e.g. a translocation or inversion) or that the heterozygous
mutation is coincidental to her phenotype, consistent with a
previous report of heterozygous null PDX1 mutations in
population controls [10].
The first cases (three patients from two families) with
biallelic PDX1 mutations [4–6] had complete pancreatic
agenesis. Subsequently, two cousins with permanent neona-
tal diabetes and subclinical exocrine insufficiency were
reported [9]. We report a further four cases with biallelic
PDX1 mutations without clinical evidence of exocrine
pancreatic insufficiency. In the two cases tested, faecal
elastase levels were normal. This suggests that the phenotype
caused by biallelic PDX1 mutations is correlated with the
mutation type. Null mutations that abolish the protein
activity cause pancreatic agenesis, while hypomorphic muta-
tions partially affecting the protein functionality lead to
permanent neonatal diabetes with or without exocrine
insufficiency.
As expected, mutations in PDX1 were more common in
cases of isolated permanent neonatal diabetes born to
consanguineous parents compared with outbred cases (2/17
vs. 1/86). Sequencing of PDX1 is recommended in patients
with isolated permanent neonatal diabetes, even in the
absence of clinical or biochemical features of pancreatic
exocrine insufficiency.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Partial pedigree of Family I. The arrow indicates
the proband. Colors indicate phenotypic features:
black = neonatal diabetes; shading grey = gestational dia-
betes; grey = adult-onset diabetes. N/N denotes no mutation
identified.
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